Connect with us

Health

European Commission Grants Ocugen Orphan Medicinal Product Designation for Gene Therapy Product Candidate, OCU400, For the Treatment of Both Retinitis Pigmentosa and Leber Congenital Amaurosis – GlobeNewswire

MALVERN, Pa., Feb. 23, 2021 (GLOBE NEWSWIRE) — Ocugen, Inc., (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and…

Published

on

ADVERTISEMENT

MALVERN, Pa., Feb. 23, 2021 (GLOBE NEWSWIRE) — Ocugen, Inc., (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that on the recommendation of the European Medicines Agency (EMA), the European Commission has granted orphan medicinal product designation for OCU400 (AAV5-hNR2E3), for the treatment of both retinitis pigmentosa (RP) and Leber…

Click here to view the original article.

Continue Reading
Advertisement

You might also like ...

Article feature image
DHHS: California COVID-19 variant found in Douglas County – KETV Omaha
Article feature image
Oregon reports 2 more COVID-19 related deaths, 455 new cases – KTVZ
Article feature image
Michigan coronavirus cases up to 587,581; Death toll now at 15,522 – WDIV ClickOnDetroit